본문 바로가기
KERD
논문KCI 등재

Flumazenil의 투여 방법에 따른 혈장내 농도와 midazolam에 의해 유도된 진정 상태의 환원 효과

Effect of adminstration method of flumazenil on the plasmaconcentration and the reversal of sedation induced by midazolam

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류치의학

초록

Flumazenil의 투여 방법에 따른 혈중 농도와 midazolam에 의해 유도된 진정 상태의 환원 효과를 평가하기 위해 23-25세의 학생을 대상으로 비강으로 midazolam을 투여하여 진정시킨 후 flumazenil을 비강내과 정맥내를 통하여 투여한 다음 액체크로마토그래피(HPLC)를 사용하여 시간 경과에 따른 혈중 농도의 변화와 함께 생징후 및 진정 정도를 측정하여 flumazenil의 길항 효과를 다각적으로 분석, 평가하여 다음과 같은 결과를 얻었다. 1. Midazolam에 의한 진정 상태에서 flumazenil의 투여시 수축기 및 이완기 혈압, 동맥혈 산소포화도 등의 생징후는 변화가 없었으나 맥박은 일시적인 상승이 있었다(P<0.05). 2. Flumazenil은 비강내 투여 및 정맥내 투여 등 투여 방법에 관계없이 midazolam에 의한 진정 상태를 일시적으로 환원시키며 투여 방법에 따른 발현 시간의 차이는 없으나 환원 정도와 지속 시간은 정맥내 투여에서 크게 나타났다(P<0.05). 3. Flumazenil의 비강내 투여는 최고 혈중 농도에 2분, 정맥내 투여는 4분 후에 각각 도달 하므로써 흡수 속도는 비강내 투여와 정맥내 투여의 차이가 크지 않았다. 4. Flumazenil의 투여 후 수 분 동안 midazolam의 혈중 농도가 일시적으로 상승하였다 (P<0.05). 이상의 결과를 종합하여 보면 flumazenil은 midazolam에 의한 진정 상태에서 생징후의 변화에 영향을 미치지 않으며 진정의 정도를 감소시키는 효과가 있고, 특히 비강내 투여는 정맥내 투여와 발현 시간에 있어서 차이가 없는 것으로 나타나 임상적으로 midazolam에 의한 부작용 발현시 응급 처치법으로 유용하게 사용할 수 있을 것으로 사료된다.

Abstract

The purpose of this study were to evaluate the effect on the reversion of sedation induced by midazolam with flumazenil and to determine the plasma concentration of flumazenil according to the method of administration. Intranasal and intravenous flumazenil were administered to sedated health volunteers aged from 23 to 25 years, in doses typical of those used clinically to induce sedation with midazolam and for reversal with flumazenil. Objective assessment for degree of sedation and vital signs, plasma concentration were made for 2 hours period. 1.Systolic and diastolic blood pressure, SpO2 were not changed by adminstration of flumazenil in sedated subject with midazolam, but pulse rate was increased temporarily. 2.Flumazenil showed the reversal of the sedative effect induced by midazolam regardless of administration methods. But intravenous administration showed more effect on the degree and the duration of reversion than intranasal administration with the exception of on set time. 3. Peak plasma concentration of flumazenil administered by intranasal route reached after 2 min and that of flumazenil administered by intravenous route was 4 min. Thus uptake of flumazenil did not showed any difference in accordance with the adminstration route. 4.Administration of flumazenil resulted in the temporary increase of midazolam plasma concentration.

참고문헌 (43)

  1. "A pharmacokinetic study of midazolam in dogs: nasal drop vs. atomizer administration.", pp.321~326 (1998)
  2. "Midazolam:a review of its use for conscious sedation of children", 15, pp.237~241 (1993)
  3. "A study of the effectiveness of oral midazolam sedation for orthodontic extraction of permanent teeth in children: a prospective, randomised, controlled, crossover trial.", pp.457~462 (2002)
  4. "Premedication of children with oral midazolam", 39, pp.545~550 (1992)
  5. "Midazolam:A review of therapeutic uses and toxicity", 15, pp.357~365 (1997)
  6. "Comparison of chloral hydrate and midazolam by mouth as premedicants in children undergoing otolaryngological surgery", 61, pp.390~396 (1988)
  7. "A rapid high-pressure liquid chromatographic procedure for determination of flumazenil in plasma", 46, pp.57~60 (2001)
  8. "A pilot study of the efficacy of oral midazolam for sedation in pediatric dental patients", 43, pp.1~8 (1996)
  9. "Pharmacokinetic and pharmacodynamic study of midazolam in children during esophago-gastroduodenoscopy", 119, pp.467~471 (1991)
  10. "Assessment of two doses of intranasal midazolam for sedation of young pediatric dental patients", 16, pp.301~305 (1994)
  11. "Tagit site of intranasally sprayed substances and their transport across the nasal mucosa:a new insight into the intranasal route of drug delivery", 23, pp.596~607 (1978)
  12. "Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray.A study in healthy volunteers", 53, pp.501~507 (2002)
  13. "Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro 15-1788", 24, pp.569~570 (1983)
  14. "Cerebral effects of high-dose midazolam and subsequent reversal with Ro 15-1788 in dogs", 68, pp.234~242 (1988)
  15. "Flumazenil in benzodiazepine antagonism Actions and clinical use in intoxications and anaesthesiology", pp.411~29 (1987)
  16. "Benzodiazepine antagonist Ro 15-1788 Antagonism of diazepam sedation in out patient undergoing gastro study", 41, pp.1184~1188 (1986)
  17. "The effects of a benzodiazepine antagonist Ro 15-1788 in the presence of stable concentrations of midazolam", 63, pp.61~64 (1985)
  18. "Feasibility of reversing benzodiazepine tolerance with flumazenil", 337, pp.133~137 (1991)
  19. "Pharmacokinetics and clinical use of flumazenil", 14, pp.1~12 (1988)
  20. "The interaction of midazolam and flumazenil on human memory and cognition", 79, pp.1183~1192 (1993)
  21. "A randomised crossover trial of post-operative cognitive and psychomotor recovery from benzodiazepine sedation:effects of reversal with flumazenil over a prolonged recovery period", 192, pp.335~339 (2002)
  22. "Reversal of benzodiazepine-induced renal vasculature relaxation with flumazenil", 449, pp.155~158 (2002)
  23. "The influence of midazolam and flumazenil on rat brain slices oxygen consumption", 47, pp.127~131 (2003)
  24. "Midazolams cardiac depressant effects and their lack of reversal by flumazenil in isolated rabbit hearts", 39, pp.283~287 (1999)
  25. "The effects of midazolam and flumazenil on psychomotor function and alertness in human volunteers", 188, pp.325~328 (2000)
  26. "Simultaneous determination of midazolam and flumazenil concentrations in human plasma by gas chromatography", 665, pp.217~221 (1995)
  27. "Memory and midazolam conscious sedation", 183, pp.399~407 (1997)
  28. "The effects of flumazenil on the reversal of midazolam sedation and amnesia in dental patients", pp.400~402 (1998)
  29. "The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects", 89, pp.395~403 (1986)
  30. "Behavioral,biochemical and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder", 36, pp.115~127 (1991)
  31. "and cardiovascular response to flumazenil no evidence for an altered benzodiazephine receptor sensitivity in panic disorder", pp.321~326 (1999)
  32. "Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788", 88, pp.1~11 (1986)
  33. "Dose-dependent effects of flumazenil on cognition,mood,and cardio-respiratory physiology in healthy volunteers", 189, pp.668~674 (2000)
  34. "Effect of flumazenil on the recovery from intravenous sedation", 90, pp.9~12 (1994)
  35. "Effect of midazolam with and without flumazenil on conditioned hypoalgesia", 53, pp.649~656 (1996)
  36. "Pharmacokinetics of flumazenil and midazolam", 70, pp.286~292 (1993)
  37. "GABAA receptor modulation of trigeminovascular nociceptive neurotransmission by midazolam is antagonized by flumazenil", 1013, pp.188~193 (2004)
  38. "Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788", 19, pp.95~98 (1985)
  39. "Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man", 27, pp.115~117 (1984)
  40. "Midazolam을 이용한 의식진정시 flumazenil의 투여경로에 따른 생징후 및 행동양상의 비교연구", 29, pp.159~166 (2002)
  41. "The effects of midazolam and flumazenil on psychomotor function", 9, pp.21~25 (1997)
  42. "Plasma concentrations of flumazenil following intranasal administration in children", 47, pp.120~124 (2000)
  43. "Clinical trial of nasal flumazenil administration", 28, pp.441~445 (2001)

관련 논문AI추천

이 간행물의 다른 논문 (22건)